Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | EDNRB | P24530 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | MC3R | P41968 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28500481 | 1.00 | GSR (0.51) | GSRCYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL1043546 | 1.00 | GSR (0.51) | GSRCYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL28552915 | 0.85 | ADRB1 (0.49) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL22813473 | 0.85 | ADRB1 (0.49) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL7511466 | 0.85 | CYP1A2 (0.50) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL21523061 | 0.85 | CYP1A2 (0.50) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL28766159 | 0.85 | CYP1A2 (0.50) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL2836232 | 0.84 | GSR (0.55) | GSRCYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL27811982 | 0.83 | ADRB1 (0.45) | ADRB1HTR2AHTR2BSIGMAR1 | |
| SCHEMBL514164 | 0.83 | CYP1A2 (0.49) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020240375-A1 | IMPROVED PROCESS FOR THE PREPARATION OF ELAGOLIX AND ITS INTERMEDIATES | DR. REDDY’S LABORATORIES LIMITED (IN) | 2020-12-03 | — | — | WO | disclosed |
| US-6906066-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040058960-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-25 | — | — | US | disclosed |
| US-20040034063-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-02-19 | — | — | US | disclosed |
| EP-1363881-A2 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Pharma Company (US) | 2003-11-26 | — | — | EP | disclosed |
| US-6605623-B1 | Prevention of asthma and other allergic diseases | BRISTOL-MYERS SQUIBB PHARMA CO. | 2003-08-12 | — | — | US | disclosed |
| US-6525069-B1 | Such as N-(t-butyl)-N'-(2-((3-(4-fluorophenyl)methyl)piperi -dinyl)methyl)cyclohexyl)urea; prevention of asthma and other allergic diseases | BRISTOL-MYERS SQUIBB PHARMA CO. | 2003-02-25 | — | — | US | disclosed |
| WO-2001098269-A2 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058960-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, CCR10 | GSR 4126/4885CYP1A2 3062/4885CYP2D6 3262/4885 |
| US-20040034063-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, CCR10 | GSR 4126/4885CYP1A2 3062/4885CYP2D6 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.